CA2307547A1 - Formulations chronotherapeutiques du diltiazem et administration de celles-ci - Google Patents

Formulations chronotherapeutiques du diltiazem et administration de celles-ci Download PDF

Info

Publication number
CA2307547A1
CA2307547A1 CA002307547A CA2307547A CA2307547A1 CA 2307547 A1 CA2307547 A1 CA 2307547A1 CA 002307547 A CA002307547 A CA 002307547A CA 2307547 A CA2307547 A CA 2307547A CA 2307547 A1 CA2307547 A1 CA 2307547A1
Authority
CA
Canada
Prior art keywords
diltiazem
given
administration
hours
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002307547A
Other languages
English (en)
Other versions
CA2307547C (fr
Inventor
Kenneth Stephen Albert
Paul Jose Maes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant International Bermuda
Original Assignee
Biovail Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25681399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2307547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA002292247A external-priority patent/CA2292247A1/fr
Application filed by Biovail Laboratories Inc filed Critical Biovail Laboratories Inc
Priority to CA002307547A priority Critical patent/CA2307547C/fr
Priority to CA002566590A priority patent/CA2566590C/fr
Priority to US09/567,451 priority patent/US7108866B1/en
Priority to DE60042168T priority patent/DE60042168D1/de
Priority to AT00930909T priority patent/ATE430561T1/de
Priority to JP2001543089A priority patent/JP2003516347A/ja
Priority to AU49037/00A priority patent/AU4903700A/en
Priority to PCT/CA2000/000593 priority patent/WO2001041744A1/fr
Priority to EP00930909A priority patent/EP1235562B1/fr
Priority to ES00930909T priority patent/ES2325826T3/es
Publication of CA2307547A1 publication Critical patent/CA2307547A1/fr
Publication of CA2307547C publication Critical patent/CA2307547C/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002307547A 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci Expired - Lifetime CA2307547C (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002307547A CA2307547C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002566590A CA2566590C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci
US09/567,451 US7108866B1 (en) 1999-12-10 2000-05-08 Chronotherapeutic diltiazem formulations and the administration thereof
ES00930909T ES2325826T3 (es) 1999-12-10 2000-05-23 Formulaciones de diltiazem cronoterapeuticas y su administracion.
JP2001543089A JP2003516347A (ja) 1999-12-10 2000-05-23 時間療法用ジルチアゼム製剤およびその投与法
AT00930909T ATE430561T1 (de) 1999-12-10 2000-05-23 Chronotherapeutische diltiazem formulierungen und deren verabreichung
DE60042168T DE60042168D1 (de) 1999-12-10 2000-05-23 Chronotherapeutische diltiazem formulierungen und deren verabreichung
AU49037/00A AU4903700A (en) 1999-12-10 2000-05-23 Chronotherapeutic diltiazem formulations and the administration thereof
PCT/CA2000/000593 WO2001041744A1 (fr) 1999-12-10 2000-05-23 Formulations a base de diltiazem chronotherapeutiques et leur administration
EP00930909A EP1235562B1 (fr) 1999-12-10 2000-05-23 Formulations a base de diltiazem chronotherapeutiques et leur administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,292,247 1999-12-10
CA002292247A CA2292247A1 (fr) 1999-12-10 1999-12-10 Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002307547A CA2307547C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002566590A Division CA2566590C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Publications (2)

Publication Number Publication Date
CA2307547A1 true CA2307547A1 (fr) 2001-06-10
CA2307547C CA2307547C (fr) 2007-08-14

Family

ID=25681399

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002566590A Expired - Lifetime CA2566590C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002307547A Expired - Lifetime CA2307547C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002566590A Expired - Lifetime CA2566590C (fr) 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Country Status (1)

Country Link
CA (2) CA2566590C (fr)

Also Published As

Publication number Publication date
CA2566590A1 (fr) 2001-06-10
CA2566590C (fr) 2008-04-15
CA2307547C (fr) 2007-08-14

Similar Documents

Publication Publication Date Title
AU4903700A (en) Chronotherapeutic diltiazem formulations and the administration thereof
CA2389235A1 (fr) Formulations d'hydrocodone a liberation lente
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
IE871981L (en) Programmed release formulation.
CA2301378A1 (fr) Composition pharmaceutique stabilisee d'un anti-inflammatoire non steroidien et d'une prostaglandine
AU2001277570A1 (en) Oral pharmaceutical composition with controlled release and prolonged absorption
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
CA2034096A1 (fr) Formulation de naproxene a liberation controlee pour administration une fois par jour
CA2385890A1 (fr) Compositions a liberation regulee contenant de la nimesulide
CA2230314A1 (fr) Formulations pharmaceutiques contenant de la darifenacine
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
CA2377299A1 (fr) Compositions pharmaceutiques orales a liberation regulee a base de mesalazine
CA2209714A1 (fr) Formulation a liberation controlee pour medicaments basiques peu solubles
WO2001041770A3 (fr) Compositions d'eplerenone nanoparticulaire
CA2366841A1 (fr) Preparation pharmaceutique contenant du tolperisone pour administration orale
RU2003100507A (ru) Фармацевтические композиции
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
CA2180178A1 (fr) Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
CA2563058C (fr) Traitement de soutien d'une maladie du foie
WO2003099214A3 (fr) Formulations de biguanide
CA2307547A1 (fr) Formulations chronotherapeutiques du diltiazem et administration de celles-ci
WO2002056867A3 (fr) Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200504